{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:28:19Z","timestamp":1782984499680,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,13]],"date-time":"2027-02-13T00:00:00Z","timestamp":1802476800000},"content-version":"am","delay-in-days":288,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K15014"],"award-info":[{"award-number":["JP25K15014"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Medical Informatics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijmedinf.2026.106337","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:42:20Z","timestamp":1770136940000},"page":"106337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Applying a statistical model-based AI method to identify prognostic factors for long-term cognitive decline in Alzheimer\u2019s disease: Evidence from pooled placebo data of four phase III trials"],"prefix":"10.1016","volume":"211","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4230-7356","authenticated-orcid":false,"given":"Ryoichi","family":"Hanazawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-9887","authenticated-orcid":false,"given":"Hiroyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-7460","authenticated-orcid":false,"given":"Akihiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijmedinf.2026.106337_b0005","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer\u2019s disease facts and figures, Alzheimers. Dement. 19 (2023) 1598\u20131695. https:\/\/doi.org\/10.1002\/alz.13016.","DOI":"10.1002\/alz.13016"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0010","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0020","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S1474-4422(15)00153-2","article-title":"Prevention of sporadic Alzheimer\u2019s disease: lessons learned from clinical trials and future directions","volume":"14","author":"Andrieu","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/JAD-215699","article-title":"Alzheimer\u2019s disease: Key insights from two decades of clinical trial failures","volume":"87","author":"Kim","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0030","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/WNL.0000000000003907","article-title":"Randomized controlled trials in mild cognitive impairment: Sources of variability","volume":"88","author":"Petersen","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/archneurol.2010.136","article-title":"A summary risk score for the prediction of Alzheimer disease in elderly persons","volume":"67","author":"Reitz","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-017-0294-2","article-title":"Early- versus late-onset Alzheimer\u2019s disease in clinical practice: cognitive and global outcomes over 3 years","volume":"9","author":"Wattmo","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0045","article-title":"Effect of apolipoprotein E \u03b54 allele on the progression of cognitive decline in the early stage of Alzheimer\u2019s disease","volume":"6","author":"Suzuki","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00857-w","article-title":"Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer\u2019s disease","volume":"13","author":"Kim","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13195-015-0127-0","article-title":"Alzheimer\u2019s disease progression by geographical region in a clinical trial setting","volume":"7","author":"Henley","year":"2015","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0060","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-142508","article-title":"Cognitive impairment precedes and predicts functional impairment in mild alzheimer\u2019s disease","volume":"47","author":"Liu-Seifert","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0065","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13195-020-00630-5","article-title":"Testing whether the progression of Alzheimer\u2019s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data","volume":"12","author":"Zhang","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0070","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1002\/sim.9504","article-title":"Estimating the longitudinal trajectory of cognitive function measurement using short-term data with different disease stages: Application in Alzheimer\u2019s disease","volume":"41","author":"Hirakawa","year":"2022","journal-title":"Stat. Med."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0075","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1109\/JBHI.2025.3546020","article-title":"Self-organized prediction-classification-superposition of longitudinal cognitive decline in Alzheimer\u2019s disease: An application to novel clinical research methodology","volume":"29","author":"Sato","year":"2025","journal-title":"IEEE J. Biomed. Health Inform."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijmedinf.2021.104510","article-title":"The need to separate the wheat from the chaff in medical informatics: Introducing a comprehensive checklist for the (self)-assessment of medical AI studies","volume":"153","author":"Cabitza","year":"2021","journal-title":"Int. J. Med. Inform."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0090","doi-asserted-by":"crossref","first-page":"S484","DOI":"10.1016\/j.jalz.2011.05.2355","article-title":"PL\u201003\u201002: Evaluating semagacestat, a gamma\u2010secretase inhibitor, in a phase III trial","volume":"7","author":"Siemers","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0100","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1185\/03007995.2014.939167","article-title":"Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings","volume":"30","author":"Henley","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0105","doi-asserted-by":"crossref","first-page":"16808","DOI":"10.1038\/s41598-020-73911-6","article-title":"Disease progression modeling of Alzheimer\u2019s disease according to education level","volume":"10","author":"Kim","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0110","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13195-022-01098-1","article-title":"Reading activities compensate for low education-related cognitive deficits","volume":"14","author":"Wang","year":"2022","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuro.2017.03.006","article-title":"Risk factors associated with the onset and progression of Alzheimer\u2019s disease: A systematic review of the evidence","volume":"61","author":"Hersi","year":"2017","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0120","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.2005.072306","article-title":"Education and rates of cognitive decline in incident Alzheimer\u2019s disease","volume":"77","author":"Scarmeas","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038268","article-title":"Education and dementia in the context of the cognitive reserve hypothesis: a systematic review with meta-analyses and qualitative analyses","volume":"7","author":"Meng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.trci.2018.06.008","article-title":"Effects of sex, educational background, and chronic kidney disease grading on longitudinal cognitive and functional decline in patients in the Japanese Alzheimer\u2019s Disease Neuroimaging Initiative study","volume":"4","author":"Iwata","year":"2018","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0135","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.trci.2019.06.004","article-title":"Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer\u2019s disease in the Japanese Alzheimer\u2019s Disease Neuroimaging Initiative study","volume":"5","author":"Yagi","year":"2019","journal-title":"Alzheimers Dement. (N. Y.)"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neurobiolaging.2019.11.017","article-title":"Education does not protect cognitive function from brain pathology in the ADNI 2 cohort","volume":"90","author":"Bauer","year":"2020","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0145","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1212\/WNL.0000000000007821","article-title":"Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship","volume":"93","author":"van Loenhoud","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0150","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14400","article-title":"Educational attainment, A\u03b2, tau, and structural brain reserve in Alzheimer\u2019s disease","volume":"21","author":"Cai","year":"2025","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0155","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1017\/S0033291709005492","article-title":"Most rapid cognitive decline in APOE epsilon4 negative Alzheimer\u2019s disease with early onset","volume":"39","author":"van der Vlies","year":"2009","journal-title":"Psychol. Med."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0160","doi-asserted-by":"crossref","first-page":"400","DOI":"10.14283\/jpad.2022.49","article-title":"Prediction of cognitive decline for enrichment of Alzheimer\u2019s disease clinical trials","volume":"9","author":"Tam","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3233\/ADR-230045","article-title":"Prognostic and predictive factors in early Alzheimer\u2019s disease: A systematic review","volume":"8","author":"Garcia","year":"2024","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0170","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/gps.2559","article-title":"The influence of ApoE4 on clinical progression of dementia: a meta-analysis","volume":"26","author":"Allan","year":"2011","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ijmedinf.2026.106337_b0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.ijmedinf.2026.106337_b0180","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1002\/alz.14134","article-title":"Scenarios for the long-term efficacy of amyloid-targeting therapies in the context of the natural history of Alzheimer\u2019s disease","volume":"20","author":"Raket","year":"2024","journal-title":"Alzheimers Dement."}],"container-title":["International Journal of Medical Informatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386505626000778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386505626000778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:44:24Z","timestamp":1772851464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386505626000778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"alternative-id":["S1386505626000778"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmedinf.2026.106337","relation":{},"ISSN":["1386-5056"],"issn-type":[{"value":"1386-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Applying a statistical model-based AI method to identify prognostic factors for long-term cognitive decline in Alzheimer\u2019s disease: Evidence from pooled placebo data of four phase III trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Medical Informatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmedinf.2026.106337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106337"}}